|Sanofi announced that the U.S. Food and Drug Administration (FDA) approved Toujeo® (insulin glargine [rDNA origin] injection, 300 U/mL), a once-daily long-acting basal insulin, to improve glycemic control in adults living with type 1 and type 2 diabetes.
Toujeo® is already in the US and is expected to be available in the EU at the end of 2015 or beginning of 2016.
"Sanofi is proud of its long heritage in diabetes and insulin therapies, including Lantus® which has supported patients in the management of their diabetes for more than a decade. With the FDA approval of Toujeo®, Sanofi builds on its strong legacy and looks forward to bringing a new treatment option to people living with diabetes," said Pierre Chancel, Senior VP, Global Diabetes, Sanofi.
The approval of Toujeo® was based on FDA review of results from the EDITION clinical trial program, which was comprised of a series of international Phase III studies evaluating the efficacy and safety of Toujeo® in more than 3,500 adults from broad and diverse diabetes populations (type 1 and type 2). In the clinical trial program leading to approval, once-daily Toujeo® was compared to that of once-daily Lantus (insulin glargine [rDNA origin] injection, 100U/mL) in open-label, randomized, active-control, parallel, treat-to-target studies of up to 26 weeks of duration with 6 months safety extension.
|"Nearly 50 percent of people living with diabetes remain uncontrolled," said John Anderson, MD, internal medicine and diabetes specialist, Frist Clinic of Nashville, TN, and Past President of the American Diabetes Association. "Despite the proven efficacy of insulin, ensuring effective titration and maintenance can be a challenge for both patients and healthcare professionals due to hypoglycemia concerns. Toujeo® provides a new option that may help patients manage their diabetes."
All studies of the EDITION program successfully met the primary study endpoints by demonstrating similar blood sugar control with Toujeo® as compared to Lantus. The most common adverse events (excluding hypoglycemia) reported for Toujeo® included nasopharyngitis (12.8% in type 1 patients and 7.1% in type 2 patients) and upper respiratory tract infection (9.5% in type 1 patients and 5.7% in type 2 patients).
Toujeo's Pharmacokinetic/Pharmacodynamic (PK/PD) information and its rates of severe and documented symptomatic hypoglycemia can be found in the label.
Toujeo® will be available in the Toujeo SoloSTAR®, a disposable prefilled pen which contains 450 units of Toujeo and requires one third of the injection volume to deliver the same number of insulin units as compared to the Lantus SoloSTAR®. The maximum single injection dose of 80 IU meets the needs of the vast majority of patients on basal insulin in the U.S., who require 80 IU or less per day. Toujeo is currently pending marketing authorization with the European Medicines Agency (EMA) and other health authorities around the world. Toujeo® is a long-acting insulin used to treat adults with type 2 and type 1 diabetes for the control of high blood sugar. It should be taken once a day at the same time each day to lower blood glucose.